Statins for Schizophrenia: A Study Examining Lovastatin as Add-On Tx
the MPR take:
Statins are believed to target several of the pathways to neuroprogression in schizophrenia, but research on the safety and efficacy of statin therapy for the treatment of schizophrenia is lacking. In the first randomized double-blind, placebo-controlled clinical trial, 36 adult inpatients with a diagnosis of schizophrenia ages 18–66 were concurrently administered risperidone (2–8mg/day) and lovastatin (20mg/day) or placebo. The starting dose of lovastatin was 10mg/day and titrated up to 20mg/day after one week. No difference in Positive and Negative Syndrome Scale (PANSS) scores were seen between the two groups at the end of the 60 day study, but there was a significant difference in the final risperidone dose between the two groups. Although risperidone and lovastatin were well tolerated with no serious adverse effects, the mean dose of risperidone was 4.8mg/day in the lovastatin group vs. 3.4mg/day in the placebo arm. While this study does not support the potential efficacy of statin augmentation of risperidone in schizophrenia, it does highlight that concurrent lovastatin with risperidone may increase the required risperidone dose vs. risperidone monotherapy in treating the clinical symptoms of schizophrenia.
While statins target many of the pathways to neuroprogression in schizophrenia, the safety and efficacy of statins for treating schizophrenia has never been examined.